Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Trabectedin

FDA-approved product (powder, intravenous), marketed as Evdi, Yondelis.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Trabectedin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Dedifferentiated liposarcoma
  • Leiomyosarcoma
  • Liposarcoma
  • Neoplasm
  • Ovarian cancer
  • Ovarian carcinoma
  • Ovarian neoplasm
  • Sarcoma
  • Soft tissue sarcoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other plant alkaloids and natural products
FDA pharmacologic class
Alkylating Drug FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli50.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae47.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis76.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Trabectedin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Trabectedin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery

    NCT03074318 · start 2017-09-28

    Registered record
    Registry ID
    NCT03074318
    Conditions
    Metastatic Leiomyosarcoma; Metastatic Liposarcoma; Unresectable Leiomyosarcoma; Unresectable Liposarcoma
    Interventions
    Avelumab; Trabectedin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2017-09-28
    Completion
    2020-11-15
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Leiomyosarcoma; Metastatic Liposarcoma; Unresectable Leiomyosarcoma; Unresectable Liposarcoma
    InterventionAvelumab; Trabectedin
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.

    NCT03085225 · start 2017-05-05

    Registered record
    Registry ID
    NCT03085225
    Conditions
    Ovarian Carcinoma; Soft Tissue Sarcoma
    Interventions
    Combination of trabectedin with durvalumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-05-05
    Completion
    2022-01-04
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Carcinoma; Soft Tissue Sarcoma
    InterventionCombination of trabectedin with durvalumab
    PhasePhase 1
    Registry statusCompleted

  • Retrospective Study in Sarcoma Patients

    NCT03284320 · start 2017-04-18

    Registered record
    Registry ID
    NCT03284320
    Conditions
    Sarcoma of Bone; Sarcoma of Soft Tissue
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-04-18
    Completion
    2021-11-01
    Enrolment
    514

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma of Bone; Sarcoma of Soft Tissue
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Geriatric Assessmen of Elderly "Unsuited" Patients Receiving Trabectedin in First Line Treatment For Advanced Soft Tissue Sarcomas (STS)

    NCT03022448 · start 2017-02-02

    Registered record
    Registry ID
    NCT03022448
    Conditions
    Advanced Soft-tissue Sarcoma; Metastatic Soft-tissue Sarcoma
    Interventions
    No Intervention
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-02-02
    Completion
    2021-12-31
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Soft-tissue Sarcoma; Metastatic Soft-tissue Sarcoma
    InterventionNo Intervention
    PhaseNot recorded
    Registry statusCompleted

  • Patient Reported Outcome Measures (PROMs) With Trabectedin

    NCT03959033 · start 2016-11-29

    Registered record
    Registry ID
    NCT03959033
    Conditions
    Sarcoma; Liposarcoma; Leiomyosarcoma
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2016-11-29
    Completion
    2019-08-28
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma; Liposarcoma; Leiomyosarcoma
    InterventionNot recorded
    PhaseNot recorded
    Registry statusTerminated

  • Retrospective Study of Trabectedin in Soft Tissue Sarcomas

    NCT02793050 · start 2016-06-15

    Registered record
    Registry ID
    NCT02793050
    Conditions
    Sarcoma, Soft Tissue
    Interventions
    Trabectedin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-06-15
    Completion
    2018-10-02
    Enrolment
    510

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma, Soft Tissue
    InterventionTrabectedin
    PhaseNot recorded
    Registry statusCompleted

  • Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients

    NCT02903004 · start 2016-04-11

    Registered record
    Registry ID
    NCT02903004
    Conditions
    Ovarian Neoplasms
    Interventions
    Trabectedin; Pegylated Liposomal Doxorubicin; Topotecan; Gemcitabine; Weekly Paclitaxel; Carboplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-04-11
    Completion
    2018-12-20
    Enrolment
    242

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Neoplasms
    InterventionTrabectedin; Pegylated Liposomal Doxorubicin; Topotecan; Gemcitabine +2 more
    PhasePhase 3
    Registry statusCompleted

  • Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide

    NCT02805725 · start 2015-12

    Registered record
    Registry ID
    NCT02805725
    Conditions
    Soft-tissue Sarcomas
    Interventions
    Phase 1: Trabectedin; Phase 2: Trabectedin; Phase 1: Cyclophosphamide; Phase 2: Cyclophosphamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2015-12
    Completion
    2021-12
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSoft-tissue Sarcomas
    InterventionPhase 1: Trabectedin; Phase 2: Trabectedin; Phase 1: Cyclophosphamide; Phase 2: Cyclophosphamide
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Trabectedin for Recurrent Grade II/III Meningioma

    NCT02234050 · start 2015-07

    Registered record
    Registry ID
    NCT02234050
    Conditions
    Recurrent High Grade Meningioma
    Interventions
    Trabectedin; Local standard of care
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-07
    Completion
    2019-01-16
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent High Grade Meningioma
    InterventionTrabectedin; Local standard of care
    PhasePhase 2
    Registry statusCompleted

  • Trial Comparing Trabectedin to the Best Supportive Care in Patients With Sarcoma

    NCT02672527 · start 2015-01-22

    Registered record
    Registry ID
    NCT02672527
    Conditions
    Soft Tissue Sarcoma
    Interventions
    Trabectedin; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-01-22
    Completion
    2018-07-14
    Enrolment
    103

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSoft Tissue Sarcoma
    InterventionTrabectedin; Dexamethasone
    PhasePhase 3
    Registry statusCompleted

  • Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS)

    NCT02398058 · start 2014-07-20

    Registered record
    Registry ID
    NCT02398058
    Conditions
    Soft Tissue Sarcoma; Bone Tumor
    Interventions
    trabectedin; olaparib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-07-20
    Completion
    2019-12-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSoft Tissue Sarcoma; Bone Tumor
    Interventiontrabectedin; olaparib
    PhasePhase 1
    Registry statusCompleted

  • Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON)

    NCT02163720 · start 2014-07-10

    Registered record
    Registry ID
    NCT02163720
    Conditions
    Ovarian Cancer
    Interventions
    Yondelis®-Caelyx®
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-07-10
    Completion
    2018-09-18
    Enrolment
    101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Cancer
    InterventionYondelis®-Caelyx®
    PhaseNot recorded
    Registry statusCompleted

  • Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma

    NCT02247544 · start 2014-03

    Registered record
    Registry ID
    NCT02247544
    Conditions
    Liposarcoma; Leiomyosarcoma
    Interventions
    Trabectedin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-03
    Completion
    2019-03-12
    Enrolment
    105

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiposarcoma; Leiomyosarcoma
    InterventionTrabectedin
    PhasePhase 2
    Registry statusCompleted

  • Trabectedin and Irinotecan for Refractory Pediatric Sarcomas

    NCT02509234 · start 2014-02

    Registered record
    Registry ID
    NCT02509234
    Conditions
    Recurrent Childhood Soft Tissue Sarcoma; Recurrent Ewing Sarcoma; Recurrent Rhabdomyosarcoma
    Interventions
    Combined chemotherapy with trabectedin followed by irinotecan
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2014-02
    Completion
    2017-07
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Childhood Soft Tissue Sarcoma; Recurrent Ewing Sarcoma; Recurrent Rhabdomyosarcoma
    InterventionCombined chemotherapy with trabectedin followed by irinotecan
    PhaseNot recorded
    Registry statusUnknown

  • A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    NCT01846611 · start 2013-10-16

    Registered record
    Registry ID
    NCT01846611
    Conditions
    Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms
    Interventions
    Trabectedin; DOXIL; Dexamethasone; DOXIL
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-10-16
    Completion
    2018-11-16
    Enrolment
    581

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms
    InterventionTrabectedin; DOXIL; Dexamethasone; DOXIL
    PhasePhase 3
    Registry statusCompleted